ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TVTX vs ERAS // 10Y YIELD & FRED MACRO BETA

Travere Therapeutics Inc. (NASDAQ) VS. Erasca Inc. (NASDAQ) • 15-METRIC TALLY: TVTX 3 — ERAS 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. ERAS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TVTX ERAS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -13.00% -35.00% +22.00 TVTX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.33% -1.82% +2.15 TVTX /fcf-yield <GO>
Operating Margin -12.80% — — TIE /operating-margins <GO>
Net Profit Margin -5.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) 110.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.44 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 TVTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.8 45.3 -9.50 ERAS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE 1.08 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 18.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $4.75B $5.02B -$269.3M ERAS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TVTX REV ERAS REV TVTX GROSS % ERAS GROSS % TVTX FCF ERAS FCF
FY 2025 $490.7M $394.5M 97.9% — $15.7M -$95.6M
FY 2024 $233.2M $502.8M 96.7% — -$248.0M -$109.5M
FY 2023 $145.2M $396.3M — — -$286.6M -$101.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
ERAS // BETA —